129 related articles for article (PubMed ID: 8383519)
1. Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts.
Kristjansen PE; Quistorff B; Spang-Thomsen M; Hansen HH
Ann Oncol; 1993 Feb; 4(2):157-60. PubMed ID: 8383519
[TBL] [Abstract][Full Text] [Related]
2. Intratumor pharmacokinetics, flow resistance, and metabolism during gemcitabine infusion in ex vivo perfused human small cell lung cancer.
Kristjansen PE; Brown TJ; Shipley LA; Jain RK
Clin Cancer Res; 1996 Feb; 2(2):359-67. PubMed ID: 9816179
[TBL] [Abstract][Full Text] [Related]
3. Different energy metabolism in two human small cell lung cancer subpopulations examined by 31P magnetic resonance spectroscopy and biochemical analysis in vivo and in vitro.
Kristjansen PE; Spang-Thomsen M; Quistorff B
Cancer Res; 1991 Oct; 51(19):5160-4. PubMed ID: 1655247
[TBL] [Abstract][Full Text] [Related]
4. Different early effect of irradiation in brain and small cell lung cancer examined by in vivo 31P-magnetic resonance spectroscopy.
Kristjansen PE; Pedersen AG; Quistorff B; Spang-Thomsen M
Radiother Oncol; 1992 Jul; 24(3):186-90. PubMed ID: 1329155
[TBL] [Abstract][Full Text] [Related]
5. Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response.
Blackstock AW; Lightfoot H; Case LD; Tepper JE; Mukherji SK; Mitchell BS; Swarts SG; Hess SM
Clin Cancer Res; 2001 Oct; 7(10):3263-8. PubMed ID: 11595723
[TBL] [Abstract][Full Text] [Related]
6. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.
Vande Voorde J; Sabuncuoğlu S; Noppen S; Hofer A; Ranjbarian F; Fieuws S; Balzarini J; Liekens S
J Biol Chem; 2014 May; 289(19):13054-65. PubMed ID: 24668817
[TBL] [Abstract][Full Text] [Related]
7. Early effects of radiotherapy in small cell lung cancer xenografts monitored by 31P magnetic resonance spectroscopy and biochemical analysis.
Kristjansen PE; Pedersen EJ; Quistorff B; Elling F; Spang-Thomsen M
Cancer Res; 1990 Aug; 50(16):4880-4. PubMed ID: 2165849
[TBL] [Abstract][Full Text] [Related]
8. Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
Lam W; Bussom S; Cheng YC
Mol Cancer Ther; 2009 Feb; 8(2):415-23. PubMed ID: 19208827
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of 2',2'-difluorodeoxycytidine (gemcitabine) and vinblastine combined with interferon in nude mice xenografts of human renal cell carcinoma.
Rohde D; Goertz M; Blatter J; Jakse G
Int J Oncol; 1998 Jun; 12(6):1367-72. PubMed ID: 9592201
[TBL] [Abstract][Full Text] [Related]
10. Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
Braakhuis BJ; Ruiz van Haperen VW; Boven E; Veerman G; Peters GJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):42-6. PubMed ID: 7481844
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
van Moorsel CJ; Bergman AM; Veerman G; Voorn DA; Ruiz van Haperen VW; Kroep JR; Pinedo HM; Peters GJ
Biochim Biophys Acta; 2000 Mar; 1474(1):5-12. PubMed ID: 10699484
[TBL] [Abstract][Full Text] [Related]
13. A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-
Sun Y; Wang J; Hao K
Molecules; 2020 May; 25(9):. PubMed ID: 32397338
[TBL] [Abstract][Full Text] [Related]
14. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
15. 19F NMR in vivo spectroscopy reflects the effectiveness of perfusion-enhancing vascular modifiers for improving gemcitabine chemotherapy.
Cron GO; Beghein N; Ansiaux R; Martinive P; Feron O; Gallez B
Magn Reson Med; 2008 Jan; 59(1):19-27. PubMed ID: 18050344
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of gemcitabine in lung cancer: part I.
Bunn PA
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-1. PubMed ID: 9194472
[No Abstract] [Full Text] [Related]
17. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
[TBL] [Abstract][Full Text] [Related]
18. Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
[TBL] [Abstract][Full Text] [Related]
20. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
